Advertisement

Topics

Philogen Company Profile

21:27 EDT 18th June 2019 | BioPortfolio

Philogen is a Swiss-Italian clinical-stage company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com.


News Articles [9 Associated News Articles listed on BioPortfolio]

Philogen raises €62mm through venture funding round

Philogen SPA (antibody-based treatments for cancer and chronic inflammatory diseases) raised €62mm ($69.6mm) from new and existing investors in an undisclosed venture round. Proceeds will support pi...

Philogen Announces Collaboration With Celgene

SIENA, Italy, January 23, 2019 /PRNewswire/ -- Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Celgene, to discov...

Philogen Raises €62m To Advance Pipeline, Expand GMP Capacity

Philogen CEO Dario Neri tells Scrip the company he co-founded now has two oncology products in Phase III development and...   

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immu...

‘Guided Missile’ Cancer Immunotherapy Boosted by €62M Funding

The Swiss-Italian biotech company Philogen has raised a private round of €62M to fund the phase III development of cancer immunotherapies that deliver immune cell-stimulating molecules directly to t...

Philogen SpA raises €62m to push registration

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

Philogen Ties-up with Big Pharma

Italy-based biotech forms discovery collaborations with J&J and Novartis

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Philogen

Philogen is a Swiss-Italian clinical-stage company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to ...

More Information about "Philogen" on BioPortfolio

We have published hundreds of Philogen news stories on BioPortfolio along with dozens of Philogen Clinical Trials and PubMed Articles about Philogen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Philogen Companies in our database. You can also find out about relevant Philogen Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record